The HIV Vaccine Funding Landscape in 2010
Abstract
This Policy Brief summarizes data on HIV vaccine R&D funding trends originally published by the HIV Vaccines and Microbicides Resource Tracking Working Group in 2011. Funding for preventive HIV vaccine R&D nearly tripled from US$ 327 million in 2000 to $961 in 2007, but subsequently dropped about 10% due to the termination of the Phase III STEP HIV vaccine trial in 2007. HIV vaccine funding has since stabilized.
Citation
Anon. The HIV Vaccine Funding Landscape in 2010. IAVI Insights, Policy Brief 28. International AIDS Vaccine Initiative (IAVI), New York, USA (2011) 4 pp.
Links
Updates to this page
Published 1 January 2011